View Exam | PowerPak

1. Which of the following patients would not be a good candidate for the single-tablet regimen of dolutegravir/lamivudine (DTG/3TC)?

A. A patient who is virologically suppressed for at least 6 months and adherent to therapy B. A patient who is naive to therapy, with a baseline HIV RNA of 400,000 copies/mL and is hepatitis B surface antigen–positive C. A person of childbearing potential using effective contraception D. A patient who is stable on tenofovir alafenamide-based triple therapy

2. Your patient, a 54-year-old man with HIV, diabetes mellitus, hypertension, moderate renal insufficiency, chronic hepatitis B, and obesity is seen for follow-up. His HIV history is notable for previously having advanced HIV disease when he was first diagnosed 4 years ago, which was complicated by Pneumocystis pneumonia and oral and esophageal candidiasis. At that time, his CD4 cell count was 10 cells/mm³, and his HIV viral load was 720,000 copies/mL. However, he has been stable for the past several years and currently is receiving tenofovir alafenamide/emtricitabine/bictegravir. His most recent CD4 cell count was 380 cells/mm³, with a viral load <20 copies/mL. If you consider switching his regimen to dolutegravir/lamivudine, which of the following findings would be an absolute contraindication to making this change?

A. CD4 cell count nadir 10 cells/mm³ B. Baseline HIV viral load >500,000 copies/mL C. Chronic hepatitis B D. Moderate renal insufficiency

3. Which of the following is true regarding weight gain and the use of antiretroviral therapy (ART)?

A. Non-nucleoside reverse transcriptase inhibitors are associated with more weight gain than integrase strand transfer inhibitors. B. Tenofovir disoproxil fumarate is associated with more weight gain than tenofovir alafenamide. C. Elvitegravir/cobicistat is associated with more weight gain than dolutegravir and bictegravir. D. Tenofovir alafenamide is associated with more weight gain than tenofovir disoproxil fumarate.

4. The VIKING study evaluated patients with HIV who had integrase inhibitor (INI) resistance. As demonstrated in that study, which of the following therapies had activity in highly treatment-experienced patients with INI-resistant virus?

A. Bictegravir-based therapy B. Once-daily dolutegravir-based therapy C. Twice-daily dolutegravir-based therapy D. Elvitegravir-based therapy

5. Which of the following studies is evaluating long-acting (LA) rilpivirine (RPV) and LA cabotegravir (CAB) in persons living with HIV who have had evidence of nonadherence for at least 6 months?

A. LATITUDE B. ATLAS-2M C. GEMINI-1 D. FLAIR

6. The HPTN 083 trial, comparing injectable long-acting cabotegravir (CAB LA) every 8 weeks with daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis, demonstrated that:

A. CAB LA was noninferior to TDF/FTC. B. TDF/FTC was superior to CAB LA. C. CAB LA was superior to TDF/FTC. D. CAB LA was not effective for pre-exposure prophylaxis.

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following patients would not be a good candidate for the single-tablet regimen of dolutegravir/lamivudine (DTG/3TC)?

3. Which of the following is true regarding weight gain and the use of antiretroviral therapy (ART)?

4. The VIKING study evaluated patients with HIV who had integrase inhibitor (INI) resistance. As demonstrated in that study, which of the following therapies had activity in highly treatment-experienced patients with INI-resistant virus?

5. Which of the following studies is evaluating long-acting (LA) rilpivirine (RPV) and LA cabotegravir (CAB) in persons living with HIV who have had evidence of nonadherence for at least 6 months?

6. The HPTN 083 trial, comparing injectable long-acting cabotegravir (CAB LA) every 8 weeks with daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis, demonstrated that:

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following patients would not be a good candidate for the single-tablet regimen of dolutegravir/lamivudine (DTG/3TC)?

3. Which of the following is true regarding weight gain and the use of antiretroviral therapy (ART)?

4. The VIKING study evaluated patients with HIV who had integrase inhibitor (INI) resistance. As demonstrated in that study, which of the following therapies had activity in highly treatment-experienced patients with INI-resistant virus?

5. Which of the following studies is evaluating long-acting (LA) rilpivirine (RPV) and LA cabotegravir (CAB) in persons living with HIV who have had evidence of nonadherence for at least 6 months?

6. The HPTN 083 trial, comparing injectable long-acting cabotegravir (CAB LA) every 8 weeks with daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis, demonstrated that:

« Return to Activity

Customers who Purchased
this Activity also Purchased